dabigatran has been researched along with Anti-Phospholipid Antibody Syndrome in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 11 (73.33) | 24.3611 |
| 2020's | 4 (26.67) | 2.80 |
| Authors | Studies |
|---|---|
| Cao, S; He, T; Wu, X; Yu, B | 1 |
| Monreal, M; Morales-Indiano, C; Olive, A; Orna, E; Santos-Gómez, M; Sarrate, E; Sorigue, M | 1 |
| De Kesel, PM; Devreese, KMJ | 1 |
| Andreoli, L; Barcellona, D; Cafolla, A; De Micheli, V; Denas, G; Falanga, A; Fierro, T; Gerosa, M; Ghirarduzzi, A; Gresele, P; Hoxha, A; Martinelli, I; Pengo, V; Prisco, D; Silvestri, E; Testa, S; Tincani, A; Tosetto, A | 1 |
| Boscolo-Anzoletti, M; Chantarangkul, V; Clerici, M; Novembrino, C; Paoletti, O; Peyvandi, F; Scalambrino, E; Testa, S; Tripodi, A | 1 |
| Johnsen, S; Lauvsnes, MB; Omdal, R | 1 |
| Curnow, J; Favaloro, EJ; Mohammed, S; Pasalic, L | 1 |
| Kopytek, M; Natorska, J; Undas, A; Ząbczyk, M | 1 |
| Arcadi, FA; Calabrò, RS; Casella, C; Genovese, C; Giorgianni, R; Marino, S; Naro, A; Portaro, S | 1 |
| Arachchillage, DJ; Cohen, H | 1 |
| Rodgers, GM; Win, K | 1 |
| Black, DF; McBane, RD; Moder, KG; Schaefer, JK; Williams, LN; Wysokinski, WE | 1 |
| Banzato, A; Hoxha, A; Pengo, V; Ruffatti, A | 1 |
| Góralczyk, T; Malec, K; Undas, A | 1 |
| Felix, SB; Greinacher, A; Hammer, F; Selleng, K; Wernicke, S | 1 |
4 review(s) available for dabigatran and Anti-Phospholipid Antibody Syndrome
| Article | Year |
|---|---|
Comparing the efficacy and safety of direct oral anticoagulants versus Vitamin K antagonists in patients with antiphospholipid syndrome: a systematic review and meta-analysis.
Topics: Administration, Oral; Anticoagulants; Antiphospholipid Syndrome; Dabigatran; Fibrinolytic Agents; Hemorrhage; Humans; Rivaroxaban; Thrombosis; Venous Thromboembolism; Vitamin K | 2022 |
Direct oral anticoagulant adsorption: Impact on lupus anticoagulant testing-Review of the literature and evaluation on spiked and patient samples.
Topics: Administration, Oral; Adsorption; Anticoagulants; Antiphospholipid Syndrome; Dabigatran; Humans; Lupus Coagulation Inhibitor; Pyridones; Rivaroxaban | 2020 |
Use of new oral anticoagulants in antiphospholipid syndrome.
Topics: Administration, Oral; Adult; Animals; Anticoagulants; Antiphospholipid Syndrome; Benzimidazoles; beta-Alanine; Breast Feeding; Clinical Trials, Phase III as Topic; Contraindications; Dabigatran; Drug Monitoring; Female; Humans; Infant, Newborn; Maternal Exposure; Morpholines; Pregnancy; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiazoles; Thiophenes | 2013 |
Detection of lupus anticoagulant in the era of direct oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Antiphospholipid Syndrome; Dabigatran; Humans; Lupus Coagulation Inhibitor; Rivaroxaban | 2017 |
1 trial(s) available for dabigatran and Anti-Phospholipid Antibody Syndrome
| Article | Year |
|---|---|
Trial of Rivaroxaban in AntiPhospholipid Syndrome (TRAPS): Two-year outcomes after the study closure.
Topics: Administration, Oral; Anticoagulants; Antiphospholipid Syndrome; Atrial Fibrillation; Dabigatran; Humans; Italy; Prospective Studies; Rivaroxaban; Stroke; Warfarin | 2021 |
10 other study(ies) available for dabigatran and Anti-Phospholipid Antibody Syndrome
| Article | Year |
|---|---|
Dabigatran for catastrophic antiphospholipid syndrome.
Topics: Anticoagulants; Antiphospholipid Syndrome; Catastrophic Illness; Dabigatran; Factor Xa Inhibitors; Humans; Male; Treatment Outcome; Vitamin K | 2019 |
Impact of a commercially available DOAC absorbent on two integrated procedures for lupus anticoagulant detection.
Topics: Administration, Oral; Anticoagulants; Antiphospholipid Syndrome; Dabigatran; Humans; Lupus Coagulation Inhibitor; Pyridones; Rivaroxaban | 2021 |
Treatment failure of direct oral anticoagulants in anti-phospholipid syndrome.
Topics: Administration, Oral; Anticoagulants; Antiphospholipid Syndrome; Dabigatran; Female; Humans; Male; Middle Aged; Thromboembolism; Treatment Failure | 2018 |
Laboratory testing for lupus anticoagulant (LA) in patients taking direct oral anticoagulants (DOACs): potential for false positives and false negatives.
Topics: Anticoagulants; Antiphospholipid Syndrome; Blood Coagulation; Blood Coagulation Tests; Dabigatran; False Negative Reactions; False Positive Reactions; Humans; Lupus Coagulation Inhibitor; Prothrombin Time; Rivaroxaban; Thrombophilia | 2019 |
The effect of DOAC-Stop on lupus anticoagulant testing in plasma samples of venous thromboembolism patients receiving direct oral anticoagulants.
Topics: Administration, Oral; Adult; Anticoagulants; Antiphospholipid Syndrome; Blood Coagulation; Blood Coagulation Tests; Dabigatran; Factor Xa Inhibitors; False Positive Reactions; Female; Humans; Lupus Coagulation Inhibitor; Male; Middle Aged; Partial Thromboplastin Time; Plasma; Prothrombin Time; Pyrazoles; Pyridones; Rivaroxaban; Venous Thromboembolism | 2019 |
New versus Old Oral Anticoagulants: How Can We Set the Scale Needle? Considerations on a Case Report.
Topics: Abortion, Spontaneous; Acenocoumarol; Adult; Antiphospholipid Syndrome; Antithrombins; Carotid Arteries; Computed Tomography Angiography; Dabigatran; Female; Follow-Up Studies; Humans; Product Surveillance, Postmarketing; Pulmonary Embolism; Stroke; Treatment Outcome; Venous Thrombosis; Warfarin | 2019 |
New oral anticoagulants may not be effective to prevent venous thromboembolism in patients with antiphospholipid syndrome.
Topics: Administration, Oral; Adult; Anticoagulants; Antiphospholipid Syndrome; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Female; Humans; Male; Middle Aged; Morpholines; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2014 |
Failure of dabigatran and rivaroxaban to prevent thromboembolism in antiphospholipid syndrome: a case series of three patients.
Topics: Adult; Anticoagulants; Antiphospholipid Syndrome; Benzimidazoles; beta-Alanine; Cerebral Infarction; Dabigatran; Drug Substitution; Female; Humans; International Normalized Ratio; Lupus Erythematosus, Systemic; Male; Mesenteric Veins; Middle Aged; Morpholines; Portal Vein; Recurrence; Retrospective Studies; Rivaroxaban; Splenic Vein; Stroke; Thiophenes; Thromboembolism; Thrombophilia; Treatment Failure; Venous Thrombosis; Warfarin | 2014 |
The use of direct oral anticoagulants in 56 patients with antiphospholipid syndrome.
Topics: Administration, Oral; Adult; Anticoagulants; Antiphospholipid Syndrome; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; Prospective Studies; Pyrazoles; Pyridones; Rivaroxaban; Thrombosis; Vitamin K; Young Adult | 2017 |
[Recurrent thromboembolisms despite full anticoagulation in a patient with antiphospholipid syndrome].
Topics: Anticoagulants; Antiphospholipid Syndrome; Antithrombins; Dabigatran; Female; Humans; International Normalized Ratio; Lupus Erythematosus, Systemic; Partial Thromboplastin Time; Pulmonary Embolism; Recurrence; Thromboembolism; Venous Thrombosis | 2017 |